Hybio Pharmaceutical (300199) — Tangible Net Worth Ratio
Hybio Pharmaceutical (300199) has a Tangible Net Worth Ratio of 36.6% as of September 2025. This metric is calculated by deducting intangible assets (CN¥422.37 Million) from net assets (CN¥666.08 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See 300199 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Hybio Pharmaceutical Tangible Net Worth Ratio (2007–2024)
This chart shows how Hybio Pharmaceutical's Tangible Net Worth Ratio has changed across 18 annual periods from 2007 to 2024. As of September 2025, the ratio stands at 36.6%, reflecting net assets of CN¥666.08 Million with intangible assets of CN¥422.37 Million CNY. See Hybio Pharmaceutical defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Hybio Pharmaceutical (2007–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Hybio Pharmaceutical from 2007 to 2024, covering 18 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see market value of Hybio Pharmaceutical.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 28.0% | CN¥597.05 Million | CN¥430.09 Million | CN¥3.01 Billion | ▼ -17.2 pp |
| 2023 | 45.2% | CN¥783.21 Million | CN¥429.59 Million | CN¥3.28 Billion | ▼ -15.7 pp |
| 2022 | 60.9% | CN¥1.30 Billion | CN¥507.30 Million | CN¥3.61 Billion | ▼ -10.0 pp |
| 2021 | 70.9% | CN¥1.65 Billion | CN¥479.20 Million | CN¥3.91 Billion | ▲ +3.8 pp |
| 2020 | 67.2% | CN¥1.68 Billion | CN¥550.89 Million | CN¥4.02 Billion | ▼ -8.1 pp |
| 2019 | 75.2% | CN¥2.23 Billion | CN¥552.89 Million | CN¥4.72 Billion | ▼ -9.4 pp |
| 2018 | 84.6% | CN¥3.39 Billion | CN¥521.03 Million | CN¥5.66 Billion | ▼ -3.7 pp |
| 2017 | 88.3% | CN¥3.88 Billion | CN¥453.90 Million | CN¥5.30 Billion | ▲ +1.4 pp |
| 2016 | 86.9% | CN¥3.60 Billion | CN¥471.82 Million | CN¥4.46 Billion | ▲ +4.6 pp |
| 2015 | 82.3% | CN¥2.64 Billion | CN¥467.05 Million | CN¥3.55 Billion | ▼ -12.9 pp |
| 2014 | 95.2% | CN¥1.30 Billion | CN¥62.70 Million | CN¥1.70 Billion | ▲ +0.2 pp |
| 2013 | 95.0% | CN¥1.12 Billion | CN¥56.28 Million | CN¥1.29 Billion | ▼ -3.6 pp |
| 2012 | 98.6% | CN¥1.02 Billion | CN¥14.23 Million | CN¥1.12 Billion | ▲ +0.2 pp |
| 2011 | 98.4% | CN¥976.09 Million | CN¥15.48 Million | CN¥1.04 Billion | ▲ +5.4 pp |
| 2010 | 93.0% | CN¥180.59 Million | CN¥12.58 Million | CN¥212.89 Million | ▲ +3.1 pp |
| 2009 | 89.9% | CN¥127.74 Million | CN¥12.84 Million | CN¥182.47 Million | ▲ +2.8 pp |
| 2008 | 87.2% | CN¥99.23 Million | CN¥12.72 Million | CN¥136.55 Million | ▼ -12.8 pp |
| 2007 | 100.0% | CN¥48.70 Million | CN¥0.00 | CN¥58.24 Million | — |